FINWIRES · TerminalLIVE
FINWIRES

Aptose Biosciences Updated Tuscany Trial Data Reported in Oral Presentation at EHA 2026

By

Aptose Biosciences (APS.TO) Monday said updated data from its Phase 1/2 Tuscany trail showed that the addition of tuspetinib to standard therapy was well-tolerated in newly diagnosed patients with AML.

The data was highlighted in an oral presentation on Sunday at the European Hematology Association Congress (EHA 2026) in Stockholm, Sweden.

According to a statement, tuspetinib in combination with standard of care dosing with venetoclax and azacitidine, creates a "well-tolerated and mutation agnostic" frontline triple drug therapy for newly diagnosed AML patients.

Thirty-two patients were dosed at varying levels. Composite complete response (CRc) rate in evaluable patients across all dosing groups was 86.2%, the company said.

MRD-negativity, which measures the presence of cancer cells after treatment, was 86.4% in patients who achieved complete response or CRh.

Aptose shares closed unchanged at $2.19 on Friday on the Toronto Stock Exchange.

Related Articles

Mining & Metals

Air Canada Customer Service Agents Ratify a New Four-Year Contract

Air Canada (AC.TO) customer service agents ratified a new four-year collective contract, Unifor, the union representing the 6,000 employees said on Friday.The union said the new contract raises the agents' compensation by 12% in the first year and 3% in each of the next three years, along with a signing bonus. The also secured improvements to shift premiums, longevity pay, as well as payment for unused sick days carried over from the previous calendar year."This agreement shows what can happen when we put their needs first. We're seeing it with meaningful gains in wages, pensions, benefits and job security, while recognizing the critical role our members play in supporting passengers every day. We are proud of what our bargaining committee achieved on behalf of members from coast-to-coast," Unifor Local 2002 President Tammy Moore said in a statement.

$AC.TO
Mining & Metals

Kootenay Silver Says Contract Miner Missing Following Accident at Columba Project

Kootenay Silver (KTN.V) said Friday a contract miner working in the F Vein shaft at its Columba project in Mexico was involved in an accident on Thursday.The miner has not yet been located despite ongoing rescue efforts, the company said, adding that it immediately notified the necessary authorities and launched a full investigation into the cause of the incident."We have temporarily stopped all exploration activities while the investigation is ongoing," the company said.Price: $1.42, Change: $-0.03, Percent Change: -2.07%

$KTN.V
Mining & Metals

Avalon Advanced Materials Appoints PJ Juvekar to Its Board of Directors

Avalon Advanced Materials (AVL.TO) on Friday said it appointed PJ Juvekar to its board of directors, effective June 8.Juvekar currently serves as a Senior Advisor with Boston Consulting Group and also serves as a Senior Advisor to Nouryon, a Carlyle-owned specialty chemicals company, said the company."Juvekar is a former top-ranked Wall Street analyst and accomplished business leader with more than 30 years of experience across capital markets, corporate strategy, and industrial sectors," stated the company.During his more than two decades at Citigroup, Juvekar held several senior leadership positions, ultimately serving as Global Head of Research for Chemicals, Agriculture, and Climate Tech, the company added."PJ brings an exceptional combination of capital markets credibility, industrial sector expertise, and strategic advisory experience that is rarely accessible to a company of Avalon's size," said board chair Alan Ferry. "As Avalon advances toward the next stage of corporate and project development, including expanded engagement with institutional investors, government stakeholders, and strategic industry participants, PJ's perspective and network will be tremendously valuable.."The company's shares were last seen up $0.005 tot $0.06 on the Toronto Stock Exchange.

$AVL.TO